Diabetes Forecast highlighted ViaCyte’s first-of-a-kind islet cell replacement therapy in an article discussing twelve innovative products being developed to treat and manage type 1 diabetes.
ViaCyte has discovered how to turn human stem cells into pancreatic precursor cells that can mature to produce insulin and control blood glucose levels in animal models. These cells are currently being tested in a Phase 1/2 clinical trial in patients with type 1 diabetes. The precursor cells are contained in ViaCyte’s semi-permeable device and implanted under the skin of diabetic patients, and preliminary clinical results have been promising.
Read more in Diabetes Forecast.